• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

5.420 +0.160 (+3.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,821
Open 5.120
Bid (Size) 5.070 (600)
Ask (Size) 5.420 (400)
Prev. Close 5.260
Today's Range 4.800 - 5.490
52wk Range 3.920 - 19.14
Shares Outstanding 101,102,152
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Atara Biotherapeutics Provides a Business Update
February 23, 2026
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
February 03, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-69.5%
-69.5%
1 Month
-1.5%
-1.5%
3 Month
-64.1%
-64.1%
6 Month
-55.0%
-55.0%
1 Year
-21.3%
-21.3%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
January 27, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
January 20, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel
January 14, 2026
Via MarketMinute
Topics Bankruptcy
The trading volume of these stocks is deviating from the norm in today's session. ↗
January 14, 2026
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
January 13, 2026
Via Chartmill
Unusual volume stocks are being observed in Tuesday's session. ↗
January 13, 2026
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session. ↗
January 12, 2026
Via Chartmill
Top stock movements in today's session. ↗
January 12, 2026
Via Chartmill
News headline image
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ ↗
January 12, 2026
Via Stocktwits
Gapping stocks in Monday's session ↗
January 12, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
January 12, 2026
Via Chartmill
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
January 12, 2026
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
January 08, 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
January 07, 2026
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
November 12, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
October 17, 2025
Via Benzinga
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
September 29, 2025
Via Benzinga
News headline image
Atara Biotherapeutics Announces Changes to Its Board of Directors
September 03, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
August 11, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
July 24, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
July 14, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
June 18, 2025
Via Benzinga
News headline image
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
May 16, 2025
From Atara Biotherapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
The current price of Atara Biotherapeutics, Inc. - Common Stock is 5.420
When was Atara Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 02/27/26 04:00 PM ET
What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 547.97M
How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
Atara Biotherapeutics, Inc. - Common Stock has 548M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap